Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a mid-size sponsor after a complete response letter, pediatric investigation plan vs. disease epidemiology is the evidence after a boxed-warning proposal from the review division. Pharmacovigilance medical reviewer has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using pediatric investigation plan vs. disease epidemiology.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using pediatric investigation plan vs. disease epidemiology after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; pediatric investigation plan vs. disease epidemiology already has the discriminator after a boxed-warning proposal from the review division. 2. Keep Pause the pathway in force until pediatric investigation plan vs. disease epidemiology is completed after a boxed-warning proposal from the review division for pharmacovigilance medical reviewer. 3. Treat pediatric investigation plan vs. disease epidemiology as Escalate safety review because both readings appear after a boxed-warning proposal from the review division. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision to drop a secondary turns on in pediatric investigation plan vs. disease epidemiology.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 2. Trace CMC, labeling, or pharmacovigilance facts in pediatric investigation plan vs. disease epidemiology after a boxed-warning proposal from the review division. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read pediatric investigation plan vs. disease epidemiology against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (pediatric investigation plan vs. disease epidemiology after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option pediatric investigation plan vs — specific to pediatric investigation plan vs. disease epidemiology after a boxed-warning proposal from the review division on this Pharma & Life Sciences CMC and Development Pathways file for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. disease epidemiology can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.